Neuroblastoma is a tumor that forms from the immature cells of the autonomic nervous system, and like other diseases of developing tissues, commonly occurs in very young children, with the median age of diagnosis being 17 months. Despite being the most common extracranial solid childhood tumor, representing about 8-10% of all childhood tumors, it presents with a wide range of symptoms and outcomes, depending on the age of the patient and degree of differentiation of the cells.  More than 50% of cases present as high risk disease, where long-term survival rates are below 50%. The amplification of the MYCN oncogene is one of the prominent indicators of aggressive disease and is found in 20% of neuroblastoma cases. What is particularly problematic is the growing evidence that aggressive neuroblastomas are resistant to standard therapies such as chemotherapy or radiation. ATP-binding transporters such as ABCC4, which are also a multi-drug resistance associated protein (MRP) and  are direct transcriptional targets of MYCN and are associated with therapeutic resistance. Here, we  investigate the IC50 concentration of Ceefourin 1 for the neuroblastoma cell lines.